text: Prescription fish oil-based medications Fish oil itself is available as a prescription, but the majority of fish oil products available via prescription are derivatives of fish oil. Such products are described elsewhere in this article. These preparations, with the purpose of treating or preventing medical disorder, are only available with a doctor's prescription. In the US, such prescriptions undergo the same Food and Drug Administration (FDA) regulatory requirements as other prescription medications, including with regard to both efficacy and safety. Purity is also regulated by the FDA. The prescription fish oil derivative medicines differ from over-the-counter fish oil supplements. Prescription fish oil is considered a safe and effective option to reduce triglycerides. There are various prescription fish oil products that have been approved and permitted by the FDA for decreasing triglyceride levels. Prescription fish oil products having DHA work by raising LDL-C levels to reduce triglycerides, like fibrates. Heart experts advise that prescription fish oil helps in decreasing additional levels of blood fats. Prescription fish oils might only help when triglycerides reach a specific upper level. Prescription fish oil pills, capsules and tablets have more omega-3 fatty acids than those which are non-prescription. The FDA regularly monitors prescription fish oil for standards like purity and for quality and safety.
  As of 2019, four fish oil-based prescription drugs have been approved in the United States for the treatment of hypertriglyceridemia, namely:
  Epanova (omega-3 carboxylic acids) was approved on 23 April 2014. Clinical trial on mixed dyslipidaemia (hypertriglyceridemia with hypocholesterolemia) started in 2014 found that it has no medical benefits, and the clinical trial was called off on 13 January 2019. Although FDA-approved, Epanova is not available in any market.
  Lovaza (omega-3 acid ethyl esters) was approved on 10 November 2004.
  Omtryg (omega-3 acid ethyl esters) was approved on 23 April 2014.